NASDAQ

Updated Nov 3, 7:59 PM ET

TARS

Tarsus Pharmaceuticals, Inc.
$73.25CS band Mixed

−$0.68 (0.93%) At close $72.64 · Today

☾After Hours +$0.61 (0.84%) Nov 3, 7:59 PM ET

Mkt Cap
$3.4B
Volume
757K
52W High
$91.53
52W Low
$53.89
PE Ratio
—
Avg Vol
903.4K
As of 11/2/26
Div Yield
—
Beta
0.63
As of 11/2/26

Company

Headquarters
Irvine, CA
Employees
370 (2026)
Listed
Oct 16, 2020
Exchange
Nasdaq
Website
tarsusrx.com
SEC industry
Biological Products, (no Diagnostic Substances)
Cylvex sector
Health Care · Biotech

Biotech

  • Market cap #26 of 146
  • P/B #16 of 131

Ranked highest first among stocks Cylvex covers.

  1. AMGNAmgen Inc$249.4B-0.90%
  2. GILDGilead Sciences Inc$207.7B-1.68%
  3. MRNAModerna Inc$91.20B+3.45%
  4. ARGXargenx SE$56.67B+2.99%
  5. RVMDRevolution Medicines, Inc.$41.63B+3.22%
All Biotech ›

Financial summary

Related companies

About

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

From company filings and market data · Not investment advice

Price data

Day Low $70.42Day High $75.37
52W Low $53.8952W High $91.53
Open
$74.30
Prev Close
$73.32
Volume
757.0K
Avg Vol (30D)
911.3K

52W range and average volume from daily bars (unadjusted, last 252 sessions).

Financials

Consensus estimates

The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.